<code id='3EAD3B5087'></code><style id='3EAD3B5087'></style>
      • <acronym id='3EAD3B5087'></acronym>
      <center id='3EAD3B5087'><center id='3EAD3B5087'><tfoot id='3EAD3B5087'></tfoot></center><abbr id='3EAD3B5087'><dir id='3EAD3B5087'><tfoot id='3EAD3B5087'></tfoot><noframes id='3EAD3B5087'>
      • <optgroup id='3EAD3B5087'><strike id='3EAD3B5087'><sup id='3EAD3B5087'></sup></strike><code id='3EAD3B5087'></code></optgroup>
        5. <b id='3EAD3B5087'><label id='3EAD3B5087'><select id='3EAD3B5087'><dt id='3EAD3B5087'><span id='3EAD3B5087'></span></dt></select></label></b><u id='3EAD3B5087'></u>
          <i id='3EAD3B5087'><strike id='3EAD3B5087'><tt id='3EAD3B5087'><pre id='3EAD3B5087'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-27 15:34:23 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：76
                                  
                                    
          
                                   
          Adam's take main illustration
          Molly Ferguson/STAT
          Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:
          A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.
          advertisement
          With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          BioAge raises $170M for combination therapy with Zepbound
                                
                            
          Next article：  
                                      
                                          Supreme Court strikes down use of affirmative action
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles